Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Pogue-Geile, Katherine L, Song, Nan, Serie, Daniel J, Wang, Ying, Gavin, Patrick G, Kim, Rim S, Tanaka, Noriko, Fumagalli, Debora, Taniyama, Yusuke, Li, Zhuo, Rastogi, Priya, Swain, Sandra M, Mamounas, Eleftherios P, Geyer, Charles E, Wolmark, Norman, Lucas, Peter C, Paik, Soonmyung, Thompson, E Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674704/
https://www.ncbi.nlm.nih.gov/pubmed/33241186
http://dx.doi.org/10.1093/jncics/pkaa058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674704/
https://www.ncbi.nlm.nih.gov/pubmed/33241186
http://dx.doi.org/10.1093/jncics/pkaa058

Ejemplares similares